Shots:

• The approval is based on results of ongoing P-III CONVERT study conducted at 18 countries with 125 sites assessing Arikayce + guideline-based therapy (GBT) vs GBT alone with refractory nontuberculous mycobacterial (NTM) lung disease caused by MAC
• P-III CONVERT study Results: ARIKAYCE+GBT reduced evidence of NTM lung disease caused by MAC in sputum @6 mos. (29% vs 9%)- showing its safety and efficacy
• ARIKAYCE is a novel therapy approved in the US for patients with MAC lung disease an also first product approved via the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

 Ref: Insmed | Image: Insmed